Latest / The Onco Life Podcast
Long-Term Immunotherapy for ASPS: AACR 2026 Breakthrough in Rare Cancer Treatment
In this episode, we break down the latest AACR 2026 breakthrough on long-term immunotherapy for alveolar soft part sarcoma (ASPS), a rare cancer that primarily affects adolescents and young adults.You’ll learn:What ASPS is and why it has been difficult to treat How immunotherapy is changing the landscape for rare cancers Key findings from the Phase II trial using atezolizumab Why long-term immunotherapy beyond two years may be safe and effective How patients maintained disease stability without increased serious side effects Common side effects and how they can be safely managed Why immune…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.